Translate this page into:
DRUG REVIEW : Review Article
doi:
10.4103/2278-330X.126527
Eribulin drug review
1
Department of Medical Oncology, Tata Memorial Hospital, Parel, Mumbai, Maharashtra
*Corresponding author: Dr. Sudeep Gupta. sudeepgupta04@yahoo.com
MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)
Disclaimer:
This article was originally published by Thieme Medical and Scientific Publishers Pvt. Ltd. and was migrated to Scientific Scholar after the change of Publisher.
This article was originally published by Thieme Medical and Scientific Publishers Pvt. Ltd. and was migrated to Scientific Scholar after the change of Publisher.
Abstract
Abstract
Eribulin is an anticancer drug approved for treatment of metastatic breast cancer. This drug is a synthetic derivative from Japanese marine sponge Halichondria okadai. It acts by interfering with the microtubular growth ultimately leading to apoptosis after prolonged mitotic blockage. In patients with metastatic breast cancer refractory to anthracyclines and taxanes, eribulin is one of the life-saving options. Neutropenia, neuropathy and QT prolongation are the most frequent adverse events associated with this drug. Phase I/II trials are also underway in refractory lung, ovarian, pancreatic, bladder, and soft tissue tumors. Larger prospective studies will define the role of this drug in a wide variety of tumors, and the future looks very promising.
Keywords
References
- Uemura D, Takahashi K, Yamamoto T, Katayama C, Tanaka J, Okumura Y et al. Norhalichondrin A: An antitumor polyether macrolide from a marine sponge. J Am Chem Soc 1985;107:4796-8.
- Swami U, Chaudhary I, Ghalib MH, Goel S. Eribulin--A review of preclinical and clinical studies. Crit Rev Oncol Hemat 2012;81:163-84.
- Donoghue M, Lemery SJ, Yuan W, He K, Sridhara R, Shord S, et al. Eribulin mesylate for the treatment of patients with refractory metastatic breast cancer: Use of a "physician′s choice" control arm in a randomized approval trial. Clin Cancer Res 2012;18:1496-505.
- Jordan M, Kamath K, Manna T, Okouneva T, Miller HP, Davis C, et al. The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Mol Cancer Ther 2005;4:1086-95.
- Tan AR, Rubin EH, Walton DC, Shuster DE, Wong YN, Fang F, et al. Phase 1 study of eribulin mesylate administered once every 21 days in patients with advanced solid tumours. Clin Cancer Res 2009;15:4213-9.
- Towle MJ, Salvato KA, Budrow J, Wels BF, Kuznetsov G, Aalfs KK, et al. In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B. Cancer Res 2001;61:1013-21.
- Aoqi K, Iwata H, Masuda N, Mukai H, Yoshida M, Rai Y, et al. A phase 2 study of eribulin in Japanese patients with heavily pretreated metastatic breast cancer. Ann Oncol 2012;23:1441-8.
- Cortes J, Vahdat L, Blum JL, Twelves C, Campone M, Roché H, et al. Phase II Study of the Halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine. J Clin Oncol 2010;28:3922-8.
- Vahdat LT, Pruitt B, Fabian CJ, Rivera RR, Smith DA, Tan-Chiu E, et al. Phase II study of eribulin mesylate, A halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2009;27:2954-61.
- Cortes J, O′Shaughnessy J, Loesch D, Blum JL, Vahdat LT, Petrakova K, et al. EMBRACE (Eisai Metastatic Breast Cancer Study Assessing Physician′s Choice Versus E7389) investigators. Eribulin monotherapy versus treatment of physician′s choice in patients with metastatic breast cancer (EMBRACE): A phase 3 open-label randomised study. Lancet 2011;377:914-23.
- Shablak A. Eribulin for advanced breast cancer: A drug evaluation. J Breast Cancer 2013;16:12-5.
- Wozniak KM, Nomoto K, Lapidus RG, Wu Y, Carozzi V, Cavaletti G, et al. Comparison of neuropathy-inducing effects of eribulin mesylate, paclitaxel, and ixabepilone in mice. Cancer Res 2011;71:3952-62.
- US Food and Drug Administration. FDA labelling information - Halaven. FDA website [online]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/201532lbl.pdf (2010) http://www.clinicaltrials.gov/ct2/results?term=eribulin+OR+E7389 [Last accessed date on 2013 Nov 15].
- Gitlitz BJ, Tsao-Wei DD, Groshen S, Davies A, Koczywas M, Belani CP, et al. A phase II study of halichondrin B analog eribulin mesylate (E7389) in patients with advanced non-small cell lung cancer previously treated with a taxane: A California cancer consortium trial. J Thorac Oncol 2012;7:574-8.